Bill Text: IL SB3025 | 2021-2022 | 102nd General Assembly | Introduced

---

Bill Title: Creates the Naturopathic Medical Practice Act. Provides for the licensure of naturopathic physicians. Creates the Naturopathic Physician Medical Board. Provides that the Board shall oversee the licensure of naturopathic physicians and matters relating to training and licensure of naturopathic physicians. Provides for membership of the Board and duties of the Board. Requires the Board to adopt rules concerning specified matters. Contains provisions concerning definitions; qualifications for licensure; approval of naturopathic medical educational programs; display of license; scope of practice; referral requirements; prohibited conduct by licensees; exemptions from the Act; title protection; license expiration, renewal, denial, revocation, and continuing education; and issuance of first licenses. Amends the Illinois Controlled Substances Act. Adds internal references to naturopathic physicians. Effective immediately.

Spectrum: Partisan Bill (Democrat 1-0)

Status: (Introduced - Dead) 2022-12-31 - Chief Sponsor Changed to Sen. Don Harmon [SB3025 Detail]

Download: Illinois-2021-SB3025-Introduced.html

---

102ND GENERAL ASSEMBLY State of Illinois 2021 and 2022 SB3025 Introduced 1/5/2022, by Sen. Melinda Bush SYNOPSIS AS INTRODUCED:
New Act
720 ILCS 570/102 from Ch. 56 1/2, par. 1102
Creates the Naturopathic Medical Practice Act. Provides for the licensure of naturopathic physicians. Creates the Naturopathic Physician Medical Board. Provides that the Board shall oversee the licensure of naturopathic physicians and matters relating to training and licensure of naturopathic physicians. Provides for membership of the Board and duties of the Board. Requires the Board to adopt rules concerning specified matters. Contains provisions concerning definitions; qualifications for licensure; approval of naturopathic medical educational programs; display of license; scope of practice; referral requirements; prohibited conduct by licensees; exemptions from the Act; title protection; license expiration, renewal, denial, revocation, and continuing education; and issuance of first licenses. Amends the Illinois Controlled Substances Act. Adds internal references to naturopathic physicians. Effective immediately.
LRB102 20970 SPS 29867 b
FISCAL NOTE ACT MAY APPLY
A BILL FOR
SB3025 LRB102 20970 SPS 29867 b
AN ACT concerning regulation.
Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
Section 1. Short title. This Act may be cited as the
Naturopathic Medical Practice Act.
Section 5. Purpose and findings. The practice of
naturopathic medicine in the State of Illinois is declared to
affect the public health, safety, and welfare and to be
subject to regulation and control in the public interest. It
is further declared to be a matter of public interest that
naturopathic physicians and the practice of naturopathic
medicine, as defined in this Act, merit the confidence of the
public, that only qualified persons be authorized to practice
naturopathic medicine in the State of Illinois, and that no
person shall practice naturopathic medicine without a valid
existing license to do so.
Illinois is facing an unprecedented physician shortage in
urban counties and an even higher shortage in rural counties.
The COVID-19 pandemic is increasing that shortage
exponentially. Naturopathic physicians with a proper scope of
practice can help fill this void.
The General Assembly recognizes that naturopathic
physicians comprise a distinct health care profession that

SB3025 - 2 - LRB102 20970 SPS 29867 b
affects the public health, safety, and welfare and that
licensure of naturopathic physicians will increase freedom of
choice in health care and help address the physician shortage
in Illinois. This Act shall be liberally construed to best
carry out these subjects and purposes.
Section 10. Definitions. In this Act:
"Approved naturopathic medical educational program" means
an educational program that the Board has approved as meeting
the requirements of Section 20 of this Act that prepares
naturopathic physicians for the practice of naturopathic
medicine.
"Association" means an entity that is approved by the
American Association of Naturopathic Physicians, which entity
represents the interests of naturopathic physicians in this
State.
"Board" means the Naturopathic Physician Medical Board
established pursuant to Section 55 of this Act.
"Clinical laboratory procedure" means the use of
venipuncture consistent with naturopathic medical practice,
commonly used diagnostic modalities consistent with
naturopathic practice, the recording of a patient's health
history, physical examination, ordering and interpretation of
radiographic diagnostics and other standard imaging and
examination of body orifices, excluding endoscopy and
colonoscopy. "Clinical laboratory procedure" includes the

SB3025 - 3 - LRB102 20970 SPS 29867 b
practice of obtaining samples of human tissues, except
surgical excision beyond surgical excision that is authorized
as a minor office procedure.
"Drug" has the same meaning as set forth in Section 102 of
the Illinois Controlled Substances Act.
"Homeopathic medicine" means a system of medicine based on
the use of infinitesimal doses of substances capable of
producing symptoms similar to those of the disease treated, as
listed in the Homeopathic Pharmacopoeia of the United States.
"Hygiene" means the use of preventive techniques,
including personal hygiene for asepsis, public health, and
safety.
"Laboratory examination" means:
(1) phlebotomy;
(2) a clinical laboratory procedure;
(3) an orificial examination;
(4) a physiological function test; and
(5) a screening or test that is consistent with
naturopathic education and training.
"Legend drug" has the same meaning as set forth in Section
3.23 of the Illinois Food, Drug and Cosmetic Act.
"License" means a license issued by the Board to an
individual pursuant to this Act and rules authorizing that
individual to practice naturopathic medicine in this State.
"Licensee" means a naturopathic physician licensed by the
Board to practice naturopathic medicine in this State.

SB3025 - 4 - LRB102 20970 SPS 29867 b
"Minor office procedure" means minor surgical care and
procedures, including:
(1) surgical care incidental to superficial
laceration, lesion, or abrasion, excluding surgical care
to treat a lesion suspected of malignancy;
(2) the removal of foreign bodies located in
superficial structures, excluding the globe of the eye;
(3) trigger point therapy;
(4) dermal stimulation;
(5) allergy testing and treatment; and
(6) the use of antiseptics and topical or local
anesthetics.
"Naturopathic medicine" means:
(1) a system of health care for the prevention,
diagnosis and treatment of human health conditions,
injury, and disease;
(2) the promotion or restoration of health; and
(3) the support and stimulation of a patient's
inherent self-healing processes through patient education
and the use of naturopathic therapies and therapeutic
substances.
"Naturopathic physical medicine" means the use of one or
more of the following physical agents in a manner consistent
with naturopathic medical practice on a part or the whole of
the body, by hand or by mechanical means, in the resolution of
a human ailment or conditions:

SB3025 - 5 - LRB102 20970 SPS 29867 b
(1) air;
(2) water;
(3) heat;
(4) cold;
(5) sound;
(6) light;
(7) electromagnetism;
(8) colon hydrotherapy;
(9) soft tissue therapy;
(10) joint mobilization;
(11) therapeutic exercise; or
(12) naturopathic manipulation.
"Naturopathic physician" means an individual licensed
pursuant to this Act as a naturopathic physician to practice
naturopathic medicine in this State.
"Naturopathic therapy" means the use of:
(1) naturopathic physical medicine;
(2) suggestion;
(3) hygiene;
(4) a therapeutic substance;
(5) nutrition and food science;
(6) homeopathic medicine;
(7) a clinical laboratory procedure; or
(8) a minor office procedure.
"Nutrition and food science" means the prevention and
treatment of disease or other human conditions through the use

SB3025 - 6 - LRB102 20970 SPS 29867 b
of food, water, herbs, roots, bark, or natural food elements.
"Prescription" has the same meaning as set forth in
Section 3 of the Pharmacy Practice Act.
"Professional examination" means a competency based
national naturopathic physician licensing examination
administered by the North American Board of Naturopathic
Examiners or its successor agency, which Board has been
nationally recognized to administer a naturopathic examination
that represents federal standards of education and training.
"Suggestion" means a technique using:
(1) biofeedback;
(2) hypnosis;
(3) health education; or
(4) health counseling.
"Therapeutic substance" means any of the following
exemplified in a standard naturopathic medical text, journal,
or pharmacopeia:
(1) a vitamin;
(2) a mineral;
(3) a nutraceutical;
(4) a botanical medicine;
(5) oxygen;
(6) a homeopathic medicine;
(7) a hormone;
(8) a hormonal or pharmaceutical contraceptive device;
or

SB3025 - 7 - LRB102 20970 SPS 29867 b
(9) other physiologic substance.
Section 15. Qualifications for licensure. The Board shall
license an applicant who:
(1) submits, in accordance with rules of the Board,
the following items to the Board:
(A) an application for licensure designed and
approved by the Board and submitted in accordance with
rules of the Board;
(B) an application fee submitted in an amount and
manner established by rules of the Board;
(C) evidence that the applicant has graduated from
an approved naturopathic medical educational program;
(D) evidence that the applicant has passed a
professional examination;
(E) evidence that the applicant has passed a
pharmacy examination authorized by rules of the Board
and administered by the North American Board of
Naturopathic Examiners or its successor;
(F) evidence that the applicant has passed a minor
surgery examination authorized by rules of the Board
and administered by the North American Board of
Naturopathic Examiners or its successor; and
(G) evidence of professional liability insurance
with policy limits not less than prescribed by the
Board;

SB3025 - 8 - LRB102 20970 SPS 29867 b
(2) is determined by the Board to be physically and
mentally capable of safely practicing naturopathic
medicine with or without reasonable accommodation; and
(3) has not had a license to practice naturopathic
medicine or other health care license, registration, or
certificate refused, revoked, or suspended by any other
jurisdiction for reasons that relate to the applicant's
ability to skillfully and safely practice naturopathic
medicine unless that license, registration, or
certification has been restored to good standing by that
jurisdiction.
Section 20. Approved naturopathic medical educational
program. The Board shall establish, by rule, guidelines for an
approved naturopathic medical educational program, which
guidelines shall meet the following requirements and the
Board's specifications for the education of naturopathic
physicians. The approved naturopathic medical educational
program shall:
(1) offer graduate-level, full-time didactic and
supervised clinical training;
(2) be accredited, or have achieved candidacy status
for accreditation, by the Council on Naturopathic Medical
Education or an equivalent federally recognized
accrediting body for naturopathic medical programs that is
also recognized by the Board; and

SB3025 - 9 - LRB102 20970 SPS 29867 b
(3) be conducted by an institution of higher
education, or a division of an institution of higher
education, that:
(A) is accredited or is a candidate for
accreditation by a regional or national institutional
accrediting agency recognized by the United States
Secretary of Education or a diploma-granting,
degree-equivalent college or university; or
(B) meets equivalent standards for recognition of
accreditation established by rules of the Board for
medical education programs offered in Canada.
Section 25. Display of license. A licensee shall display
the licensee's license in the licensee's place of business in
a location clearly visible to the licensee's patients and
shall also display evidence of the licensee having completed
an approved naturopathic medical educational program.
Section 30. Scope of practice. A licensee may practice
naturopathic medicine to provide primary care in alignment
with naturopathic medical education to:
(1) perform physical examinations;
(2) order laboratory examinations;
(3) order diagnostic imaging studies;
(4) interpret the results of laboratory examinations
for diagnostic purposes;

SB3025 - 10 - LRB102 20970 SPS 29867 b
(5) order and, based on a radiologist's report, take
action on diagnostic imaging studies in a manner
consistent with naturopathic training;
(6) prescribe, administer, dispense, and order food,
extracts of food, nutraceuticals, vitamins, amino acids,
minerals, enzymes, botanicals and their extracts,
botanical medicines, homeopathic medicines, dietary
supplements, and nonprescription drugs as defined by the
Federal Food, Drug, and Cosmetic Act;
(7) prescribe, administer, dispense, and order all
legend drugs and all drugs within Schedules II-V of the
Controlled Substances Act;
(8) administer intramuscular, intravenous,
subcutaneous, intra-articular and intradermal injections
of substances appropriate to naturopathic medicine;
(9) use routes of administration that include oral,
nasal, auricular, ocular, rectal, vaginal, transdermal,
intradermal, subcutaneous, intravenous, intra-articular,
and intramuscular consistent with the education and
training of a naturopathic physician;
(10) perform naturopathic physical medicine;
(11) employ the use of naturopathic therapy;
(12) use therapeutic devices, barrier contraception,
intrauterine devices, hormonal and pharmaceutical
contraception, and durable medical equipment; or
(13) perform minor office procedures.

SB3025 - 11 - LRB102 20970 SPS 29867 b
Section 35. Referral requirement. A licensee shall refer
to a physician licensed to practice medicine in all of its
branches under the Medical Practice Act of 1987 any patient
whose medical condition is determined, at the time of
evaluation or treatment, to be beyond the scope of practice of
the licensee.
Section 40. Prohibitions. A licensee shall not:
(1) perform surgery outside of the scope of minor
office procedures permitted in the employment of
naturopathic therapy;
(2) use general or spinal anesthetics;
(3) administer ionizing radioactive substances for
therapeutic purposes;
(4) perform a surgical procedure using a laser device;
(5) perform a surgical procedure involving any of the
following areas of the body that extend beyond superficial
tissue:
(A) eyes;
(B) ears;
(C) tendons;
(D) nerves;
(E) veins; or
(F) arteries;
(6) perform a surgical abortion;

SB3025 - 12 - LRB102 20970 SPS 29867 b
(7) treat any lesion suspected of malignancy or
requiring surgical removal; or
(8) perform acupuncture.
Section 45. Exemptions. Nothing in this Act shall be
construed to prohibit or to restrict:
(1) the practice of a health care profession by an
individual who is licensed, certified, or registered under
other laws of this State and who is performing services
within the individual's authorized scope of practice;
(2) the practice of naturopathic medicine by a student
enrolled in an approved naturopathic medical educational
program if the practice of naturopathic medicine by a
student is performed pursuant to a course of instruction
or an assignment from an instructor at an accredited
university or college by an instructor duly licensed as a
health care provider in Illinois;
(3) any person that sells a vitamin or herb from
providing information about the vitamin or herb;
(4) the practice of naturopathic medicine by persons
who are licensed to practice in any other state or
district in the United States and who enter this State to
consult with a naturopathic physician of this State if the
consultation is limited to examination, recommendation, or
testimony in litigation; or
(5) any person or practitioner who is not licensed as

SB3025 - 13 - LRB102 20970 SPS 29867 b
a naturopathic physician from recommending ayurvedic
medicine, herbal remedies, nutritional advice, homeopathy,
or other therapy that is within the scope of practice of
naturopathic medicine; however, the person or practitioner
shall not:
(A) use a title protected pursuant to Section 50
of this Act;
(B) represent or assume the character or
appearance of a licensee; or
(C) otherwise use a name, title, or other
designation that indicates or implies that the person
is a licensee.
Section 50. Protected titles.
(a) A licensee shall use the title "naturopathic
physician", "naturopathic doctor", or "naturopathic medical
doctor" and the recognized abbreviations "N.D." and "N.M.D.".
(b) A licensee has the exclusive right to use the
following terms in reference to the licensee's self:
(1) "naturopathic physician";
(2) "naturopathic doctor";
(3) "naturopathic medical doctor";
(4) "doctor of naturopathic medicine";
(5) "doctor of naturopathy";
(6) "naturopath";
(7) "N.D.";

SB3025 - 14 - LRB102 20970 SPS 29867 b
(8) "ND";
(9) "NMD"; and
(10) "N.M.D.".
(c) An individual represents the individual's self to be a
naturopathic physician or a naturopathic doctor when the
individual uses or adopts any of the following terms in
reference to the individual's self:
(1) "naturopathic physician";
(2) "naturopathic doctor";
(3) "naturopathic medical doctor";
(4) "doctor of naturopathic medicine";
(5) "doctor of naturopathy";
(6) "naturopath";
(7) "N.D.";
(8) "ND";
(9) "NMD"; and
(10) "N.M.D.".
(d) An individual shall not represent the individual's
self to the public as a naturopathic physician, naturopathic
doctor, naturopathic medical doctor, a doctor of naturopathic
medicine, a doctor of naturopathy, or as being otherwise
authorized to practice naturopathic medicine in this State,
unless the individual is a licensee.
Section 55. Naturopathic Physician Medical Board.
(a) The Naturopathic Physician Medical Board shall

SB3025 - 15 - LRB102 20970 SPS 29867 b
oversee:
(1) licensure of naturopathic physicians; and
(2) matters relating to training and licensure of
naturopathic physicians.
(b) Within 90 days after the effective date of this Act,
the Governor shall appoint an initial Board consisting of 2
members for terms of 4 years each, 3 members for terms of 3
years each, and 4 members for terms of 2 years each. The
initial Board shall consist of 9 voting members as follows:
(1) five licensed naturopathic physicians who are
residents of Illinois and are members of the Illinois
Association of Naturopathic Physicians;
(2) two practicing physicians licensed to practice
medicine in all of its branches with experience working
with naturopathic physicians; and
(3) two public members that are residents of this
State who are not, and never have been, a licensed health
care practitioner and who do not have an interest in
naturopathic education, naturopathic medicine, or
naturopathic business or practice.
(c) As the terms of the initial Board members expire, the
Governor shall appoint successors for terms of 4 years each as
follows:
(1) five naturopathic physicians licensed pursuant to
this Act;
(2) two practicing physicians licensed to practice

SB3025 - 16 - LRB102 20970 SPS 29867 b
medicine in all of its branches with experience working
with naturopathic physicians; and
(3) two public members that are residents of this
State who are not, and never have been, a licensed health
care practitioner and who do not have an interest in
naturopathic education, naturopathic medicine or
naturopathic business or practice.
(d) Within 30 days after the Board is established, the
Board shall call the first meeting, at which meeting members
shall elect a chair. At least once during each calendar
quarter thereafter, the Board shall hold a meeting at the call
of the chair. The Board may hold additional meetings at the
call of the chair or at the written request of any 2 members of
the Board.
(e) Vacancies on the Board shall be filled from a list of
not fewer than 3 candidates provided by the Illinois
Association of Naturopathic Physicians.
(f) A majority of the Board membership shall constitute a
quorum.
(g) Members of the Board shall serve without compensation
but may, at the discretion of the Board, be reimbursed for
their expenses incurred in performing their duties.
(h) The Department of Financial and Professional
Regulation shall provide administrative and other support to
the Board.

SB3025 - 17 - LRB102 20970 SPS 29867 b
Section 60. Board duties. The Board shall adopt rules:
(1) regulating the licensure of naturopathic
physicians and determining the hours of continuing
education units required for maintaining licensure as a
naturopathic physician;
(2) prescribing the manner in which records of
examinations and treatments shall be kept and maintained;
(3) establishing standards for professional
responsibility and conduct;
(4) identifying disciplinary actions and circumstances
that require disciplinary action;
(5) developing a means to provide information to all
licensees in this State;
(6) providing for the investigation of complaints
against licensees or persons holding themselves out as
naturopathic physicians in this State;
(7) providing for the publication of information for
the public about licensees and the practice of
naturopathic medicine in this State;
(8) providing for an orderly process for reinstatement
of a license;
(9) establishing criteria for advertising or
promotional materials;
(10) establishing continuing education hours and
content;
(11) establishing procedures and standards for

SB3025 - 18 - LRB102 20970 SPS 29867 b
reviewing licensing examination scores; and
(12) establishing procedures for reviewing transcripts
demonstrating completion of the approved naturopathic
medical educational program;
(13) establishing and maintaining a list of
naturopathic medical education programs that meet the
requirements of Section 20;
(14) establishing the requirements for issuance and
renewal of licenses; and
(15) any other matter necessary to implement this Act.
Section 65. License expiration, renewal, denial,
revocation, and continuing education.
(a) A license issued or renewed pursuant to this Act shall
expire in a time frame determined by the Board.
(b) The Board may renew the license of any licensee who,
upon the expiration of the licensee's license:
(1) has submitted an application for renewal;
(2) has paid the renewal fee established by rules of
the Board;
(3) meets the qualifications for licensure set forth
in this Act and rules of the Board; and
(4) meets the continuing education requirements
established by the Board.
(c) If the Board intends to refuse to issue or renew,
revoke, or suspend a license, the Board shall grant the

SB3025 - 19 - LRB102 20970 SPS 29867 b
applicant or licensee an opportunity for a hearing.
Section 70. Issuance of first licenses. On a schedule
determined by the Board, the Board shall issue licenses to
those applicants who have met the requirements of this Act and
Board rules adopted in accordance with this Act.
Section 100. The Illinois Controlled Substances Act is
amended by changing Section 102 as follows:
(720 ILCS 570/102) (from Ch. 56 1/2, par. 1102)
(Text of Section before amendment by P.A. 101-666)
Sec. 102. Definitions. As used in this Act, unless the
context otherwise requires:
(a) "Addict" means any person who habitually uses any
drug, chemical, substance or dangerous drug other than alcohol
so as to endanger the public morals, health, safety or welfare
or who is so far addicted to the use of a dangerous drug or
controlled substance other than alcohol as to have lost the
power of self control with reference to his or her addiction.
(b) "Administer" means the direct application of a
controlled substance, whether by injection, inhalation,
ingestion, or any other means, to the body of a patient,
research subject, or animal (as defined by the Humane
Euthanasia in Animal Shelters Act) by:
(1) a practitioner (or, in his or her presence, by his

SB3025 - 20 - LRB102 20970 SPS 29867 b
or her authorized agent),
(2) the patient or research subject pursuant to an
order, or
(3) a euthanasia technician as defined by the Humane
Euthanasia in Animal Shelters Act.
(c) "Agent" means an authorized person who acts on behalf
of or at the direction of a manufacturer, distributor,
dispenser, prescriber, or practitioner. It does not include a
common or contract carrier, public warehouseman or employee of
the carrier or warehouseman.
(c-1) "Anabolic Steroids" means any drug or hormonal
substance, chemically and pharmacologically related to
testosterone (other than estrogens, progestins,
corticosteroids, and dehydroepiandrosterone), and includes:
(i) 3[beta],17-dihydroxy-5a-androstane,
(ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,
(iii) 5[alpha]-androstan-3,17-dione,
(iv) 1-androstenediol (3[beta],
17[beta]-dihydroxy-5[alpha]-androst-1-ene),
(v) 1-androstenediol (3[alpha],
17[beta]-dihydroxy-5[alpha]-androst-1-ene),
(vi) 4-androstenediol
(3[beta],17[beta]-dihydroxy-androst-4-ene),
(vii) 5-androstenediol
(3[beta],17[beta]-dihydroxy-androst-5-ene),
(viii) 1-androstenedione

SB3025 - 21 - LRB102 20970 SPS 29867 b
([5alpha]-androst-1-en-3,17-dione),
(ix) 4-androstenedione
(androst-4-en-3,17-dione),
(x) 5-androstenedione
(androst-5-en-3,17-dione),
(xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-
hydroxyandrost-4-en-3-one),
(xii) boldenone (17[beta]-hydroxyandrost-
1,4,-diene-3-one),
(xiii) boldione (androsta-1,4-
diene-3,17-dione),
(xiv) calusterone (7[beta],17[alpha]-dimethyl-17
[beta]-hydroxyandrost-4-en-3-one),
(xv) clostebol (4-chloro-17[beta]-
hydroxyandrost-4-en-3-one),
(xvi) dehydrochloromethyltestosterone (4-chloro-
17[beta]-hydroxy-17[alpha]-methyl-
androst-1,4-dien-3-one),
(xvii) desoxymethyltestosterone
(17[alpha]-methyl-5[alpha]
-androst-2-en-17[beta]-ol)(a.k.a., madol),
(xviii) [delta]1-dihydrotestosterone (a.k.a.
'1-testosterone') (17[beta]-hydroxy-
5[alpha]-androst-1-en-3-one),
(xix) 4-dihydrotestosterone (17[beta]-hydroxy-
androstan-3-one),

SB3025 - 22 - LRB102 20970 SPS 29867 b
(xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-
5[alpha]-androstan-3-one),
(xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-
hydroxyestr-4-ene),
(xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-
1[beta],17[beta]-dihydroxyandrost-4-en-3-one),
(xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],
17[beta]-dihydroxyandrost-1,4-dien-3-one),
(xxiv) furazabol (17[alpha]-methyl-17[beta]-
hydroxyandrostano[2,3-c]-furazan),
(xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one,
(xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-
androst-4-en-3-one),
(xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-
dihydroxy-estr-4-en-3-one),
(xxviii) mestanolone (17[alpha]-methyl-17[beta]-
hydroxy-5-androstan-3-one),
(xxix) mesterolone (1amethyl-17[beta]-hydroxy-
[5a]-androstan-3-one),
(xxx) methandienone (17[alpha]-methyl-17[beta]-
hydroxyandrost-1,4-dien-3-one),
(xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]-
dihydroxyandrost-5-ene),
(xxxii) methenolone (1-methyl-17[beta]-hydroxy-
5[alpha]-androst-1-en-3-one),
(xxxiii) 17[alpha]-methyl-3[beta], 17[beta]-

SB3025 - 23 - LRB102 20970 SPS 29867 b
dihydroxy-5a-androstane,
(xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy
-5a-androstane,
(xxxv) 17[alpha]-methyl-3[beta],17[beta]-
dihydroxyandrost-4-ene),
(xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-
methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),
(xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-
hydroxyestra-4,9(10)-dien-3-one),
(xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-
hydroxyestra-4,9-11-trien-3-one),
(xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-
hydroxyandrost-4-en-3-one),
(xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-
hydroxyestr-4-en-3-one),
(xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
(17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-
androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl-
1-testosterone'),
(xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),
(xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-
dihydroxyestr-4-ene),
(xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-
dihydroxyestr-4-ene),
(xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-
dihydroxyestr-5-ene),

SB3025 - 24 - LRB102 20970 SPS 29867 b
(xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-
dihydroxyestr-5-ene),
(xlvii) 19-nor-4,9(10)-androstadienedione
(estra-4,9(10)-diene-3,17-dione),
(xlviii) 19-nor-4-androstenedione (estr-4-
en-3,17-dione),
(xlix) 19-nor-5-androstenedione (estr-5-
en-3,17-dione),
(l) norbolethone (13[beta], 17a-diethyl-17[beta]-
hydroxygon-4-en-3-one),
(li) norclostebol (4-chloro-17[beta]-
hydroxyestr-4-en-3-one),
(lii) norethandrolone (17[alpha]-ethyl-17[beta]-
hydroxyestr-4-en-3-one),
(liii) normethandrolone (17[alpha]-methyl-17[beta]-
hydroxyestr-4-en-3-one),
(liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-
2-oxa-5[alpha]-androstan-3-one),
(lv) oxymesterone (17[alpha]-methyl-4,17[beta]-
dihydroxyandrost-4-en-3-one),
(lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-
17[beta]-hydroxy-(5[alpha]-androstan-3-one),
(lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-
(5[alpha]-androst-2-eno[3,2-c]-pyrazole),
(lviii) stenbolone (17[beta]-hydroxy-2-methyl-
(5[alpha]-androst-1-en-3-one),

SB3025 - 25 - LRB102 20970 SPS 29867 b
(lix) testolactone (13-hydroxy-3-oxo-13,17-
secoandrosta-1,4-dien-17-oic
acid lactone),
(lx) testosterone (17[beta]-hydroxyandrost-
4-en-3-one),
(lxi) tetrahydrogestrinone (13[beta], 17[alpha]-
diethyl-17[beta]-hydroxygon-
4,9,11-trien-3-one),
(lxii) trenbolone (17[beta]-hydroxyestr-4,9,
11-trien-3-one).
Any person who is otherwise lawfully in possession of an
anabolic steroid, or who otherwise lawfully manufactures,
distributes, dispenses, delivers, or possesses with intent to
deliver an anabolic steroid, which anabolic steroid is
expressly intended for and lawfully allowed to be administered
through implants to livestock or other nonhuman species, and
which is approved by the Secretary of Health and Human
Services for such administration, and which the person intends
to administer or have administered through such implants,
shall not be considered to be in unauthorized possession or to
unlawfully manufacture, distribute, dispense, deliver, or
possess with intent to deliver such anabolic steroid for
purposes of this Act.
(d) "Administration" means the Drug Enforcement
Administration, United States Department of Justice, or its
successor agency.

SB3025 - 26 - LRB102 20970 SPS 29867 b
(d-5) "Clinical Director, Prescription Monitoring Program"
means a Department of Human Services administrative employee
licensed to either prescribe or dispense controlled substances
who shall run the clinical aspects of the Department of Human
Services Prescription Monitoring Program and its Prescription
Information Library.
(d-10) "Compounding" means the preparation and mixing of
components, excluding flavorings, (1) as the result of a
prescriber's prescription drug order or initiative based on
the prescriber-patient-pharmacist relationship in the course
of professional practice or (2) for the purpose of, or
incident to, research, teaching, or chemical analysis and not
for sale or dispensing. "Compounding" includes the preparation
of drugs or devices in anticipation of receiving prescription
drug orders based on routine, regularly observed dispensing
patterns. Commercially available products may be compounded
for dispensing to individual patients only if both of the
following conditions are met: (i) the commercial product is
not reasonably available from normal distribution channels in
a timely manner to meet the patient's needs and (ii) the
prescribing practitioner has requested that the drug be
compounded.
(e) "Control" means to add a drug or other substance, or
immediate precursor, to a Schedule whether by transfer from
another Schedule or otherwise.
(f) "Controlled Substance" means (i) a drug, substance,

SB3025 - 27 - LRB102 20970 SPS 29867 b
immediate precursor, or synthetic drug in the Schedules of
Article II of this Act or (ii) a drug or other substance, or
immediate precursor, designated as a controlled substance by
the Department through administrative rule. The term does not
include distilled spirits, wine, malt beverages, or tobacco,
as those terms are defined or used in the Liquor Control Act of
1934 and the Tobacco Products Tax Act of 1995.
(f-5) "Controlled substance analog" means a substance:
(1) the chemical structure of which is substantially
similar to the chemical structure of a controlled
substance in Schedule I or II;
(2) which has a stimulant, depressant, or
hallucinogenic effect on the central nervous system that
is substantially similar to or greater than the stimulant,
depressant, or hallucinogenic effect on the central
nervous system of a controlled substance in Schedule I or
II; or
(3) with respect to a particular person, which such
person represents or intends to have a stimulant,
depressant, or hallucinogenic effect on the central
nervous system that is substantially similar to or greater
than the stimulant, depressant, or hallucinogenic effect
on the central nervous system of a controlled substance in
Schedule I or II.
(g) "Counterfeit substance" means a controlled substance,
which, or the container or labeling of which, without

SB3025 - 28 - LRB102 20970 SPS 29867 b
authorization bears the trademark, trade name, or other
identifying mark, imprint, number or device, or any likeness
thereof, of a manufacturer, distributor, or dispenser other
than the person who in fact manufactured, distributed, or
dispensed the substance.
(h) "Deliver" or "delivery" means the actual, constructive
or attempted transfer of possession of a controlled substance,
with or without consideration, whether or not there is an
agency relationship.
(i) "Department" means the Illinois Department of Human
Services (as successor to the Department of Alcoholism and
Substance Abuse) or its successor agency.
(j) (Blank).
(k) "Department of Corrections" means the Department of
Corrections of the State of Illinois or its successor agency.
(l) "Department of Financial and Professional Regulation"
means the Department of Financial and Professional Regulation
of the State of Illinois or its successor agency.
(m) "Depressant" means any drug that (i) causes an overall
depression of central nervous system functions, (ii) causes
impaired consciousness and awareness, and (iii) can be
habit-forming or lead to a substance abuse problem, including
but not limited to alcohol, cannabis and its active principles
and their analogs, benzodiazepines and their analogs,
barbiturates and their analogs, opioids (natural and
synthetic) and their analogs, and chloral hydrate and similar

SB3025 - 29 - LRB102 20970 SPS 29867 b
sedative hypnotics.
(n) (Blank).
(o) "Director" means the Director of the Illinois State
Police or his or her designated agents.
(p) "Dispense" means to deliver a controlled substance to
an ultimate user or research subject by or pursuant to the
lawful order of a prescriber, including the prescribing,
administering, packaging, labeling, or compounding necessary
to prepare the substance for that delivery.
(q) "Dispenser" means a practitioner who dispenses.
(r) "Distribute" means to deliver, other than by
administering or dispensing, a controlled substance.
(s) "Distributor" means a person who distributes.
(t) "Drug" means (1) substances recognized as drugs in the
official United States Pharmacopoeia, Official Homeopathic
Pharmacopoeia of the United States, or official National
Formulary, or any supplement to any of them; (2) substances
intended for use in diagnosis, cure, mitigation, treatment, or
prevention of disease in man or animals; (3) substances (other
than food) intended to affect the structure of any function of
the body of man or animals and (4) substances intended for use
as a component of any article specified in clause (1), (2), or
(3) of this subsection. It does not include devices or their
components, parts, or accessories.
(t-3) "Electronic health record" or "EHR" means an
electronic record of health-related information on an

SB3025 - 30 - LRB102 20970 SPS 29867 b
individual that is created, gathered, managed, and consulted
by authorized health care clinicians and staff.
(t-4) "Emergency medical services personnel" has the
meaning ascribed to it in the Emergency Medical Services (EMS)
Systems Act.
(t-5) "Euthanasia agency" means an entity certified by the
Department of Financial and Professional Regulation for the
purpose of animal euthanasia that holds an animal control
facility license or animal shelter license under the Animal
Welfare Act. A euthanasia agency is authorized to purchase,
store, possess, and utilize Schedule II nonnarcotic and
Schedule III nonnarcotic drugs for the sole purpose of animal
euthanasia.
(t-10) "Euthanasia drugs" means Schedule II or Schedule
III substances (nonnarcotic controlled substances) that are
used by a euthanasia agency for the purpose of animal
euthanasia.
(u) "Good faith" means the prescribing or dispensing of a
controlled substance by a practitioner in the regular course
of professional treatment to or for any person who is under his
or her treatment for a pathology or condition other than that
individual's physical or psychological dependence upon or
addiction to a controlled substance, except as provided
herein: and application of the term to a pharmacist shall mean
the dispensing of a controlled substance pursuant to the
prescriber's order which in the professional judgment of the

SB3025 - 31 - LRB102 20970 SPS 29867 b
pharmacist is lawful. The pharmacist shall be guided by
accepted professional standards including, but not limited to
the following, in making the judgment:
(1) lack of consistency of prescriber-patient
relationship,
(2) frequency of prescriptions for same drug by one
prescriber for large numbers of patients,
(3) quantities beyond those normally prescribed,
(4) unusual dosages (recognizing that there may be
clinical circumstances where more or less than the usual
dose may be used legitimately),
(5) unusual geographic distances between patient,
pharmacist and prescriber,
(6) consistent prescribing of habit-forming drugs.
(u-0.5) "Hallucinogen" means a drug that causes markedly
altered sensory perception leading to hallucinations of any
type.
(u-1) "Home infusion services" means services provided by
a pharmacy in compounding solutions for direct administration
to a patient in a private residence, long-term care facility,
or hospice setting by means of parenteral, intravenous,
intramuscular, subcutaneous, or intraspinal infusion.
(u-5) "Illinois State Police" means the State Police of
the State of Illinois, or its successor agency.
(v) "Immediate precursor" means a substance:
(1) which the Department has found to be and by rule

SB3025 - 32 - LRB102 20970 SPS 29867 b
designated as being a principal compound used, or produced
primarily for use, in the manufacture of a controlled
substance;
(2) which is an immediate chemical intermediary used
or likely to be used in the manufacture of such controlled
substance; and
(3) the control of which is necessary to prevent,
curtail or limit the manufacture of such controlled
substance.
(w) "Instructional activities" means the acts of teaching,
educating or instructing by practitioners using controlled
substances within educational facilities approved by the State
Board of Education or its successor agency.
(x) "Local authorities" means a duly organized State,
County or Municipal peace unit or police force.
(y) "Look-alike substance" means a substance, other than a
controlled substance which (1) by overall dosage unit
appearance, including shape, color, size, markings or lack
thereof, taste, consistency, or any other identifying physical
characteristic of the substance, would lead a reasonable
person to believe that the substance is a controlled
substance, or (2) is expressly or impliedly represented to be
a controlled substance or is distributed under circumstances
which would lead a reasonable person to believe that the
substance is a controlled substance. For the purpose of
determining whether the representations made or the

SB3025 - 33 - LRB102 20970 SPS 29867 b
circumstances of the distribution would lead a reasonable
person to believe the substance to be a controlled substance
under this clause (2) of subsection (y), the court or other
authority may consider the following factors in addition to
any other factor that may be relevant:
(a) statements made by the owner or person in control
of the substance concerning its nature, use or effect;
(b) statements made to the buyer or recipient that the
substance may be resold for profit;
(c) whether the substance is packaged in a manner
normally used for the illegal distribution of controlled
substances;
(d) whether the distribution or attempted distribution
included an exchange of or demand for money or other
property as consideration, and whether the amount of the
consideration was substantially greater than the
reasonable retail market value of the substance.
Clause (1) of this subsection (y) shall not apply to a
noncontrolled substance in its finished dosage form that was
initially introduced into commerce prior to the initial
introduction into commerce of a controlled substance in its
finished dosage form which it may substantially resemble.
Nothing in this subsection (y) prohibits the dispensing or
distributing of noncontrolled substances by persons authorized
to dispense and distribute controlled substances under this
Act, provided that such action would be deemed to be carried

SB3025 - 34 - LRB102 20970 SPS 29867 b
out in good faith under subsection (u) if the substances
involved were controlled substances.
Nothing in this subsection (y) or in this Act prohibits
the manufacture, preparation, propagation, compounding,
processing, packaging, advertising or distribution of a drug
or drugs by any person registered pursuant to Section 510 of
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
(y-1) "Mail-order pharmacy" means a pharmacy that is
located in a state of the United States that delivers,
dispenses or distributes, through the United States Postal
Service or other common carrier, to Illinois residents, any
substance which requires a prescription.
(z) "Manufacture" means the production, preparation,
propagation, compounding, conversion or processing of a
controlled substance other than methamphetamine, either
directly or indirectly, by extraction from substances of
natural origin, or independently by means of chemical
synthesis, or by a combination of extraction and chemical
synthesis, and includes any packaging or repackaging of the
substance or labeling of its container, except that this term
does not include:
(1) by an ultimate user, the preparation or
compounding of a controlled substance for his or her own
use; or
(2) by a practitioner, or his or her authorized agent
under his or her supervision, the preparation,

SB3025 - 35 - LRB102 20970 SPS 29867 b
compounding, packaging, or labeling of a controlled
substance:
(a) as an incident to his or her administering or
dispensing of a controlled substance in the course of
his or her professional practice; or
(b) as an incident to lawful research, teaching or
chemical analysis and not for sale.
(z-1) (Blank).
(z-5) "Medication shopping" means the conduct prohibited
under subsection (a) of Section 314.5 of this Act.
(z-10) "Mid-level practitioner" means (i) a physician
assistant who has been delegated authority to prescribe
through a written delegation of authority by a physician
licensed to practice medicine in all of its branches, in
accordance with Section 7.5 of the Physician Assistant
Practice Act of 1987, (ii) an advanced practice registered
nurse who has been delegated authority to prescribe through a
written delegation of authority by a physician licensed to
practice medicine in all of its branches or by a podiatric
physician, in accordance with Section 65-40 of the Nurse
Practice Act, (iii) an advanced practice registered nurse
certified as a nurse practitioner, nurse midwife, or clinical
nurse specialist who has been granted authority to prescribe
by a hospital affiliate in accordance with Section 65-45 of
the Nurse Practice Act, (iv) an animal euthanasia agency, or
(v) a prescribing psychologist.

SB3025 - 36 - LRB102 20970 SPS 29867 b
(aa) "Narcotic drug" means any of the following, whether
produced directly or indirectly by extraction from substances
of vegetable origin, or independently by means of chemical
synthesis, or by a combination of extraction and chemical
synthesis:
(1) opium, opiates, derivatives of opium and opiates,
including their isomers, esters, ethers, salts, and salts
of isomers, esters, and ethers, whenever the existence of
such isomers, esters, ethers, and salts is possible within
the specific chemical designation; however the term
"narcotic drug" does not include the isoquinoline
alkaloids of opium;
(2) (blank);
(3) opium poppy and poppy straw;
(4) coca leaves, except coca leaves and extracts of
coca leaves from which substantially all of the cocaine
and ecgonine, and their isomers, derivatives and salts,
have been removed;
(5) cocaine, its salts, optical and geometric isomers,
and salts of isomers;
(6) ecgonine, its derivatives, their salts, isomers,
and salts of isomers;
(7) any compound, mixture, or preparation which
contains any quantity of any of the substances referred to
in subparagraphs (1) through (6).
(bb) "Nurse" means a registered nurse licensed under the

SB3025 - 37 - LRB102 20970 SPS 29867 b
Nurse Practice Act.
(cc) (Blank).
(dd) "Opiate" means any substance having an addiction
forming or addiction sustaining liability similar to morphine
or being capable of conversion into a drug having addiction
forming or addiction sustaining liability.
(ee) "Opium poppy" means the plant of the species Papaver
somniferum L., except its seeds.
(ee-5) "Oral dosage" means a tablet, capsule, elixir, or
solution or other liquid form of medication intended for
administration by mouth, but the term does not include a form
of medication intended for buccal, sublingual, or transmucosal
administration.
(ff) "Parole and Pardon Board" means the Parole and Pardon
Board of the State of Illinois or its successor agency.
(gg) "Person" means any individual, corporation,
mail-order pharmacy, government or governmental subdivision or
agency, business trust, estate, trust, partnership or
association, or any other entity.
(hh) "Pharmacist" means any person who holds a license or
certificate of registration as a registered pharmacist, a
local registered pharmacist or a registered assistant
pharmacist under the Pharmacy Practice Act.
(ii) "Pharmacy" means any store, ship or other place in
which pharmacy is authorized to be practiced under the
Pharmacy Practice Act.

SB3025 - 38 - LRB102 20970 SPS 29867 b
(ii-5) "Pharmacy shopping" means the conduct prohibited
under subsection (b) of Section 314.5 of this Act.
(ii-10) "Physician" (except when the context otherwise
requires) means a person licensed to practice medicine in all
of its branches.
(jj) "Poppy straw" means all parts, except the seeds, of
the opium poppy, after mowing.
(kk) "Practitioner" means a physician licensed to practice
medicine in all its branches, dentist, optometrist, podiatric
physician, naturopathic physician, veterinarian, scientific
investigator, pharmacist, physician assistant, advanced
practice registered nurse, licensed practical nurse,
registered nurse, emergency medical services personnel,
hospital, laboratory, or pharmacy, or other person licensed,
registered, or otherwise lawfully permitted by the United
States or this State to distribute, dispense, conduct research
with respect to, administer or use in teaching or chemical
analysis, a controlled substance in the course of professional
practice or research.
(ll) "Pre-printed prescription" means a written
prescription upon which the designated drug has been indicated
prior to the time of issuance; the term does not mean a written
prescription that is individually generated by machine or
computer in the prescriber's office.
(mm) "Prescriber" means a physician licensed to practice
medicine in all its branches, dentist, optometrist,

SB3025 - 39 - LRB102 20970 SPS 29867 b
prescribing psychologist licensed under Section 4.2 of the
Clinical Psychologist Licensing Act with prescriptive
authority delegated under Section 4.3 of the Clinical
Psychologist Licensing Act, podiatric physician, naturopathic
physician, or veterinarian who issues a prescription, a
physician assistant who issues a prescription for a controlled
substance in accordance with Section 303.05, a written
delegation, and a written collaborative agreement required
under Section 7.5 of the Physician Assistant Practice Act of
1987, an advanced practice registered nurse with prescriptive
authority delegated under Section 65-40 of the Nurse Practice
Act and in accordance with Section 303.05, a written
delegation, and a written collaborative agreement under
Section 65-35 of the Nurse Practice Act, an advanced practice
registered nurse certified as a nurse practitioner, nurse
midwife, or clinical nurse specialist who has been granted
authority to prescribe by a hospital affiliate in accordance
with Section 65-45 of the Nurse Practice Act and in accordance
with Section 303.05, or an advanced practice registered nurse
certified as a nurse practitioner, nurse midwife, or clinical
nurse specialist who has full practice authority pursuant to
Section 65-43 of the Nurse Practice Act.
(nn) "Prescription" means a written, facsimile, or oral
order, or an electronic order that complies with applicable
federal requirements, of a physician licensed to practice
medicine in all its branches, dentist, podiatric physician,

SB3025 - 40 - LRB102 20970 SPS 29867 b
naturopathic physician, or veterinarian for any controlled
substance, of an optometrist in accordance with Section 15.1
of the Illinois Optometric Practice Act of 1987, of a
prescribing psychologist licensed under Section 4.2 of the
Clinical Psychologist Licensing Act with prescriptive
authority delegated under Section 4.3 of the Clinical
Psychologist Licensing Act, of a physician assistant for a
controlled substance in accordance with Section 303.05, a
written delegation, and a written collaborative agreement
required under Section 7.5 of the Physician Assistant Practice
Act of 1987, of an advanced practice registered nurse with
prescriptive authority delegated under Section 65-40 of the
Nurse Practice Act who issues a prescription for a controlled
substance in accordance with Section 303.05, a written
delegation, and a written collaborative agreement under
Section 65-35 of the Nurse Practice Act, of an advanced
practice registered nurse certified as a nurse practitioner,
nurse midwife, or clinical nurse specialist who has been
granted authority to prescribe by a hospital affiliate in
accordance with Section 65-45 of the Nurse Practice Act and in
accordance with Section 303.05 when required by law, or of an
advanced practice registered nurse certified as a nurse
practitioner, nurse midwife, or clinical nurse specialist who
has full practice authority pursuant to Section 65-43 of the
Nurse Practice Act.
(nn-5) "Prescription Information Library" (PIL) means an

SB3025 - 41 - LRB102 20970 SPS 29867 b
electronic library that contains reported controlled substance
data.
(nn-10) "Prescription Monitoring Program" (PMP) means the
entity that collects, tracks, and stores reported data on
controlled substances and select drugs pursuant to Section
316.
(oo) "Production" or "produce" means manufacture,
planting, cultivating, growing, or harvesting of a controlled
substance other than methamphetamine.
(pp) "Registrant" means every person who is required to
register under Section 302 of this Act.
(qq) "Registry number" means the number assigned to each
person authorized to handle controlled substances under the
laws of the United States and of this State.
(qq-5) "Secretary" means, as the context requires, either
the Secretary of the Department or the Secretary of the
Department of Financial and Professional Regulation, and the
Secretary's designated agents.
(rr) "State" includes the State of Illinois and any state,
district, commonwealth, territory, insular possession thereof,
and any area subject to the legal authority of the United
States of America.
(rr-5) "Stimulant" means any drug that (i) causes an
overall excitation of central nervous system functions, (ii)
causes impaired consciousness and awareness, and (iii) can be
habit-forming or lead to a substance abuse problem, including

SB3025 - 42 - LRB102 20970 SPS 29867 b
but not limited to amphetamines and their analogs,
methylphenidate and its analogs, cocaine, and phencyclidine
and its analogs.
(rr-10) "Synthetic drug" includes, but is not limited to,
any synthetic cannabinoids or piperazines or any synthetic
cathinones as provided for in Schedule I.
(ss) "Ultimate user" means a person who lawfully possesses
a controlled substance for his or her own use or for the use of
a member of his or her household or for administering to an
animal owned by him or her or by a member of his or her
household.
(Source: P.A. 99-78, eff. 7-20-15; 99-173, eff. 7-29-15;
99-371, eff. 1-1-16; 99-480, eff. 9-9-15; 99-642, eff.
7-28-16; 100-280, eff. 1-1-18; 100-453, eff. 8-25-17; 100-513,
eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff. 8-14-18.)
(Text of Section after amendment by P.A. 101-666)
Sec. 102. Definitions. As used in this Act, unless the
context otherwise requires:
(a) "Addict" means any person who habitually uses any
drug, chemical, substance or dangerous drug other than alcohol
so as to endanger the public morals, health, safety or welfare
or who is so far addicted to the use of a dangerous drug or
controlled substance other than alcohol as to have lost the
power of self control with reference to his or her addiction.
(b) "Administer" means the direct application of a

SB3025 - 43 - LRB102 20970 SPS 29867 b
controlled substance, whether by injection, inhalation,
ingestion, or any other means, to the body of a patient,
research subject, or animal (as defined by the Humane
Euthanasia in Animal Shelters Act) by:
(1) a practitioner (or, in his or her presence, by his
or her authorized agent),
(2) the patient or research subject pursuant to an
order, or
(3) a euthanasia technician as defined by the Humane
Euthanasia in Animal Shelters Act.
(c) "Agent" means an authorized person who acts on behalf
of or at the direction of a manufacturer, distributor,
dispenser, prescriber, or practitioner. It does not include a
common or contract carrier, public warehouseman or employee of
the carrier or warehouseman.
(c-1) "Anabolic Steroids" means any drug or hormonal
substance, chemically and pharmacologically related to
testosterone (other than estrogens, progestins,
corticosteroids, and dehydroepiandrosterone), and includes:
(i) 3[beta],17-dihydroxy-5a-androstane,
(ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,
(iii) 5[alpha]-androstan-3,17-dione,
(iv) 1-androstenediol (3[beta],
17[beta]-dihydroxy-5[alpha]-androst-1-ene),
(v) 1-androstenediol (3[alpha],
17[beta]-dihydroxy-5[alpha]-androst-1-ene),

SB3025 - 44 - LRB102 20970 SPS 29867 b
(vi) 4-androstenediol
(3[beta],17[beta]-dihydroxy-androst-4-ene),
(vii) 5-androstenediol
(3[beta],17[beta]-dihydroxy-androst-5-ene),
(viii) 1-androstenedione
([5alpha]-androst-1-en-3,17-dione),
(ix) 4-androstenedione
(androst-4-en-3,17-dione),
(x) 5-androstenedione
(androst-5-en-3,17-dione),
(xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-
hydroxyandrost-4-en-3-one),
(xii) boldenone (17[beta]-hydroxyandrost-
1,4,-diene-3-one),
(xiii) boldione (androsta-1,4-
diene-3,17-dione),
(xiv) calusterone (7[beta],17[alpha]-dimethyl-17
[beta]-hydroxyandrost-4-en-3-one),
(xv) clostebol (4-chloro-17[beta]-
hydroxyandrost-4-en-3-one),
(xvi) dehydrochloromethyltestosterone (4-chloro-
17[beta]-hydroxy-17[alpha]-methyl-
androst-1,4-dien-3-one),
(xvii) desoxymethyltestosterone
(17[alpha]-methyl-5[alpha]
-androst-2-en-17[beta]-ol)(a.k.a., madol),

SB3025 - 45 - LRB102 20970 SPS 29867 b
(xviii) [delta]1-dihydrotestosterone (a.k.a.
'1-testosterone') (17[beta]-hydroxy-
5[alpha]-androst-1-en-3-one),
(xix) 4-dihydrotestosterone (17[beta]-hydroxy-
androstan-3-one),
(xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-
5[alpha]-androstan-3-one),
(xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-
hydroxyestr-4-ene),
(xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-
1[beta],17[beta]-dihydroxyandrost-4-en-3-one),
(xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],
17[beta]-dihydroxyandrost-1,4-dien-3-one),
(xxiv) furazabol (17[alpha]-methyl-17[beta]-
hydroxyandrostano[2,3-c]-furazan),
(xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one,
(xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-
androst-4-en-3-one),
(xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-
dihydroxy-estr-4-en-3-one),
(xxviii) mestanolone (17[alpha]-methyl-17[beta]-
hydroxy-5-androstan-3-one),
(xxix) mesterolone (1amethyl-17[beta]-hydroxy-
[5a]-androstan-3-one),
(xxx) methandienone (17[alpha]-methyl-17[beta]-
hydroxyandrost-1,4-dien-3-one),

SB3025 - 46 - LRB102 20970 SPS 29867 b
(xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]-
dihydroxyandrost-5-ene),
(xxxii) methenolone (1-methyl-17[beta]-hydroxy-
5[alpha]-androst-1-en-3-one),
(xxxiii) 17[alpha]-methyl-3[beta], 17[beta]-
dihydroxy-5a-androstane,
(xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy
-5a-androstane,
(xxxv) 17[alpha]-methyl-3[beta],17[beta]-
dihydroxyandrost-4-ene),
(xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-
methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),
(xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-
hydroxyestra-4,9(10)-dien-3-one),
(xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-
hydroxyestra-4,9-11-trien-3-one),
(xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-
hydroxyandrost-4-en-3-one),
(xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-
hydroxyestr-4-en-3-one),
(xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
(17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-
androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl-
1-testosterone'),
(xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),
(xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-

SB3025 - 47 - LRB102 20970 SPS 29867 b
dihydroxyestr-4-ene),
(xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-
dihydroxyestr-4-ene),
(xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-
dihydroxyestr-5-ene),
(xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-
dihydroxyestr-5-ene),
(xlvii) 19-nor-4,9(10)-androstadienedione
(estra-4,9(10)-diene-3,17-dione),
(xlviii) 19-nor-4-androstenedione (estr-4-
en-3,17-dione),
(xlix) 19-nor-5-androstenedione (estr-5-
en-3,17-dione),
(l) norbolethone (13[beta], 17a-diethyl-17[beta]-
hydroxygon-4-en-3-one),
(li) norclostebol (4-chloro-17[beta]-
hydroxyestr-4-en-3-one),
(lii) norethandrolone (17[alpha]-ethyl-17[beta]-
hydroxyestr-4-en-3-one),
(liii) normethandrolone (17[alpha]-methyl-17[beta]-
hydroxyestr-4-en-3-one),
(liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-
2-oxa-5[alpha]-androstan-3-one),
(lv) oxymesterone (17[alpha]-methyl-4,17[beta]-
dihydroxyandrost-4-en-3-one),
(lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-

SB3025 - 48 - LRB102 20970 SPS 29867 b
17[beta]-hydroxy-(5[alpha]-androstan-3-one),
(lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-
(5[alpha]-androst-2-eno[3,2-c]-pyrazole),
(lviii) stenbolone (17[beta]-hydroxy-2-methyl-
(5[alpha]-androst-1-en-3-one),
(lix) testolactone (13-hydroxy-3-oxo-13,17-
secoandrosta-1,4-dien-17-oic
acid lactone),
(lx) testosterone (17[beta]-hydroxyandrost-
4-en-3-one),
(lxi) tetrahydrogestrinone (13[beta], 17[alpha]-
diethyl-17[beta]-hydroxygon-
4,9,11-trien-3-one),
(lxii) trenbolone (17[beta]-hydroxyestr-4,9,
11-trien-3-one).
Any person who is otherwise lawfully in possession of an
anabolic steroid, or who otherwise lawfully manufactures,
distributes, dispenses, delivers, or possesses with intent to
deliver an anabolic steroid, which anabolic steroid is
expressly intended for and lawfully allowed to be administered
through implants to livestock or other nonhuman species, and
which is approved by the Secretary of Health and Human
Services for such administration, and which the person intends
to administer or have administered through such implants,
shall not be considered to be in unauthorized possession or to
unlawfully manufacture, distribute, dispense, deliver, or

SB3025 - 49 - LRB102 20970 SPS 29867 b
possess with intent to deliver such anabolic steroid for
purposes of this Act.
(d) "Administration" means the Drug Enforcement
Administration, United States Department of Justice, or its
successor agency.
(d-5) "Clinical Director, Prescription Monitoring Program"
means a Department of Human Services administrative employee
licensed to either prescribe or dispense controlled substances
who shall run the clinical aspects of the Department of Human
Services Prescription Monitoring Program and its Prescription
Information Library.
(d-10) "Compounding" means the preparation and mixing of
components, excluding flavorings, (1) as the result of a
prescriber's prescription drug order or initiative based on
the prescriber-patient-pharmacist relationship in the course
of professional practice or (2) for the purpose of, or
incident to, research, teaching, or chemical analysis and not
for sale or dispensing. "Compounding" includes the preparation
of drugs or devices in anticipation of receiving prescription
drug orders based on routine, regularly observed dispensing
patterns. Commercially available products may be compounded
for dispensing to individual patients only if both of the
following conditions are met: (i) the commercial product is
not reasonably available from normal distribution channels in
a timely manner to meet the patient's needs and (ii) the
prescribing practitioner has requested that the drug be

SB3025 - 50 - LRB102 20970 SPS 29867 b
compounded.
(e) "Control" means to add a drug or other substance, or
immediate precursor, to a Schedule whether by transfer from
another Schedule or otherwise.
(f) "Controlled Substance" means (i) a drug, substance,
immediate precursor, or synthetic drug in the Schedules of
Article II of this Act or (ii) a drug or other substance, or
immediate precursor, designated as a controlled substance by
the Department through administrative rule. The term does not
include distilled spirits, wine, malt beverages, or tobacco,
as those terms are defined or used in the Liquor Control Act of
1934 and the Tobacco Products Tax Act of 1995.
(f-5) "Controlled substance analog" means a substance:
(1) the chemical structure of which is substantially
similar to the chemical structure of a controlled
substance in Schedule I or II;
(2) which has a stimulant, depressant, or
hallucinogenic effect on the central nervous system that
is substantially similar to or greater than the stimulant,
depressant, or hallucinogenic effect on the central
nervous system of a controlled substance in Schedule I or
II; or
(3) with respect to a particular person, which such
person represents or intends to have a stimulant,
depressant, or hallucinogenic effect on the central
nervous system that is substantially similar to or greater

SB3025 - 51 - LRB102 20970 SPS 29867 b
than the stimulant, depressant, or hallucinogenic effect
on the central nervous system of a controlled substance in
Schedule I or II.
(g) "Counterfeit substance" means a controlled substance,
which, or the container or labeling of which, without
authorization bears the trademark, trade name, or other
identifying mark, imprint, number or device, or any likeness
thereof, of a manufacturer, distributor, or dispenser other
than the person who in fact manufactured, distributed, or
dispensed the substance.
(h) "Deliver" or "delivery" means the actual, constructive
or attempted transfer of possession of a controlled substance,
with or without consideration, whether or not there is an
agency relationship.
(i) "Department" means the Illinois Department of Human
Services (as successor to the Department of Alcoholism and
Substance Abuse) or its successor agency.
(j) (Blank).
(k) "Department of Corrections" means the Department of
Corrections of the State of Illinois or its successor agency.
(l) "Department of Financial and Professional Regulation"
means the Department of Financial and Professional Regulation
of the State of Illinois or its successor agency.
(m) "Depressant" means any drug that (i) causes an overall
depression of central nervous system functions, (ii) causes
impaired consciousness and awareness, and (iii) can be

SB3025 - 52 - LRB102 20970 SPS 29867 b
habit-forming or lead to a substance abuse problem, including
but not limited to alcohol, cannabis and its active principles
and their analogs, benzodiazepines and their analogs,
barbiturates and their analogs, opioids (natural and
synthetic) and their analogs, and chloral hydrate and similar
sedative hypnotics.
(n) (Blank).
(o) "Director" means the Director of the Illinois State
Police or his or her designated agents.
(p) "Dispense" means to deliver a controlled substance to
an ultimate user or research subject by or pursuant to the
lawful order of a prescriber, including the prescribing,
administering, packaging, labeling, or compounding necessary
to prepare the substance for that delivery.
(q) "Dispenser" means a practitioner who dispenses.
(r) "Distribute" means to deliver, other than by
administering or dispensing, a controlled substance.
(s) "Distributor" means a person who distributes.
(t) "Drug" means (1) substances recognized as drugs in the
official United States Pharmacopoeia, Official Homeopathic
Pharmacopoeia of the United States, or official National
Formulary, or any supplement to any of them; (2) substances
intended for use in diagnosis, cure, mitigation, treatment, or
prevention of disease in man or animals; (3) substances (other
than food) intended to affect the structure of any function of
the body of man or animals and (4) substances intended for use

SB3025 - 53 - LRB102 20970 SPS 29867 b
as a component of any article specified in clause (1), (2), or
(3) of this subsection. It does not include devices or their
components, parts, or accessories.
(t-3) "Electronic health record" or "EHR" means an
electronic record of health-related information on an
individual that is created, gathered, managed, and consulted
by authorized health care clinicians and staff.
(t-3.5) "Electronic health record system" or "EHR system"
means any computer-based system or combination of federally
certified Health IT Modules (defined at 42 CFR 170.102 or its
successor) used as a repository for electronic health records
and accessed or updated by a prescriber or authorized
surrogate in the ordinary course of his or her medical
practice. For purposes of connecting to the Prescription
Information Library maintained by the Bureau of Pharmacy and
Clinical Support Systems or its successor, an EHR system may
connect to the Prescription Information Library directly or
through all or part of a computer program or system that is a
federally certified Health IT Module maintained by a third
party and used by the EHR system to secure access to the
database.
(t-4) "Emergency medical services personnel" has the
meaning ascribed to it in the Emergency Medical Services (EMS)
Systems Act.
(t-5) "Euthanasia agency" means an entity certified by the
Department of Financial and Professional Regulation for the

SB3025 - 54 - LRB102 20970 SPS 29867 b
purpose of animal euthanasia that holds an animal control
facility license or animal shelter license under the Animal
Welfare Act. A euthanasia agency is authorized to purchase,
store, possess, and utilize Schedule II nonnarcotic and
Schedule III nonnarcotic drugs for the sole purpose of animal
euthanasia.
(t-10) "Euthanasia drugs" means Schedule II or Schedule
III substances (nonnarcotic controlled substances) that are
used by a euthanasia agency for the purpose of animal
euthanasia.
(u) "Good faith" means the prescribing or dispensing of a
controlled substance by a practitioner in the regular course
of professional treatment to or for any person who is under his
or her treatment for a pathology or condition other than that
individual's physical or psychological dependence upon or
addiction to a controlled substance, except as provided
herein: and application of the term to a pharmacist shall mean
the dispensing of a controlled substance pursuant to the
prescriber's order which in the professional judgment of the
pharmacist is lawful. The pharmacist shall be guided by
accepted professional standards including, but not limited to
the following, in making the judgment:
(1) lack of consistency of prescriber-patient
relationship,
(2) frequency of prescriptions for same drug by one
prescriber for large numbers of patients,

SB3025 - 55 - LRB102 20970 SPS 29867 b
(3) quantities beyond those normally prescribed,
(4) unusual dosages (recognizing that there may be
clinical circumstances where more or less than the usual
dose may be used legitimately),
(5) unusual geographic distances between patient,
pharmacist and prescriber,
(6) consistent prescribing of habit-forming drugs.
(u-0.5) "Hallucinogen" means a drug that causes markedly
altered sensory perception leading to hallucinations of any
type.
(u-1) "Home infusion services" means services provided by
a pharmacy in compounding solutions for direct administration
to a patient in a private residence, long-term care facility,
or hospice setting by means of parenteral, intravenous,
intramuscular, subcutaneous, or intraspinal infusion.
(u-5) "Illinois State Police" means the State Police of
the State of Illinois, or its successor agency.
(v) "Immediate precursor" means a substance:
(1) which the Department has found to be and by rule
designated as being a principal compound used, or produced
primarily for use, in the manufacture of a controlled
substance;
(2) which is an immediate chemical intermediary used
or likely to be used in the manufacture of such controlled
substance; and
(3) the control of which is necessary to prevent,

SB3025 - 56 - LRB102 20970 SPS 29867 b
curtail or limit the manufacture of such controlled
substance.
(w) "Instructional activities" means the acts of teaching,
educating or instructing by practitioners using controlled
substances within educational facilities approved by the State
Board of Education or its successor agency.
(x) "Local authorities" means a duly organized State,
County or Municipal peace unit or police force.
(y) "Look-alike substance" means a substance, other than a
controlled substance which (1) by overall dosage unit
appearance, including shape, color, size, markings or lack
thereof, taste, consistency, or any other identifying physical
characteristic of the substance, would lead a reasonable
person to believe that the substance is a controlled
substance, or (2) is expressly or impliedly represented to be
a controlled substance or is distributed under circumstances
which would lead a reasonable person to believe that the
substance is a controlled substance. For the purpose of
determining whether the representations made or the
circumstances of the distribution would lead a reasonable
person to believe the substance to be a controlled substance
under this clause (2) of subsection (y), the court or other
authority may consider the following factors in addition to
any other factor that may be relevant:
(a) statements made by the owner or person in control
of the substance concerning its nature, use or effect;

SB3025 - 57 - LRB102 20970 SPS 29867 b
(b) statements made to the buyer or recipient that the
substance may be resold for profit;
(c) whether the substance is packaged in a manner
normally used for the illegal distribution of controlled
substances;
(d) whether the distribution or attempted distribution
included an exchange of or demand for money or other
property as consideration, and whether the amount of the
consideration was substantially greater than the
reasonable retail market value of the substance.
Clause (1) of this subsection (y) shall not apply to a
noncontrolled substance in its finished dosage form that was
initially introduced into commerce prior to the initial
introduction into commerce of a controlled substance in its
finished dosage form which it may substantially resemble.
Nothing in this subsection (y) prohibits the dispensing or
distributing of noncontrolled substances by persons authorized
to dispense and distribute controlled substances under this
Act, provided that such action would be deemed to be carried
out in good faith under subsection (u) if the substances
involved were controlled substances.
Nothing in this subsection (y) or in this Act prohibits
the manufacture, preparation, propagation, compounding,
processing, packaging, advertising or distribution of a drug
or drugs by any person registered pursuant to Section 510 of
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).

SB3025 - 58 - LRB102 20970 SPS 29867 b
(y-1) "Mail-order pharmacy" means a pharmacy that is
located in a state of the United States that delivers,
dispenses or distributes, through the United States Postal
Service or other common carrier, to Illinois residents, any
substance which requires a prescription.
(z) "Manufacture" means the production, preparation,
propagation, compounding, conversion or processing of a
controlled substance other than methamphetamine, either
directly or indirectly, by extraction from substances of
natural origin, or independently by means of chemical
synthesis, or by a combination of extraction and chemical
synthesis, and includes any packaging or repackaging of the
substance or labeling of its container, except that this term
does not include:
(1) by an ultimate user, the preparation or
compounding of a controlled substance for his or her own
use; or
(2) by a practitioner, or his or her authorized agent
under his or her supervision, the preparation,
compounding, packaging, or labeling of a controlled
substance:
(a) as an incident to his or her administering or
dispensing of a controlled substance in the course of
his or her professional practice; or
(b) as an incident to lawful research, teaching or
chemical analysis and not for sale.

SB3025 - 59 - LRB102 20970 SPS 29867 b
(z-1) (Blank).
(z-5) "Medication shopping" means the conduct prohibited
under subsection (a) of Section 314.5 of this Act.
(z-10) "Mid-level practitioner" means (i) a physician
assistant who has been delegated authority to prescribe
through a written delegation of authority by a physician
licensed to practice medicine in all of its branches, in
accordance with Section 7.5 of the Physician Assistant
Practice Act of 1987, (ii) an advanced practice registered
nurse who has been delegated authority to prescribe through a
written delegation of authority by a physician licensed to
practice medicine in all of its branches or by a podiatric
physician, in accordance with Section 65-40 of the Nurse
Practice Act, (iii) an advanced practice registered nurse
certified as a nurse practitioner, nurse midwife, or clinical
nurse specialist who has been granted authority to prescribe
by a hospital affiliate in accordance with Section 65-45 of
the Nurse Practice Act, (iv) an animal euthanasia agency, or
(v) a prescribing psychologist.
(aa) "Narcotic drug" means any of the following, whether
produced directly or indirectly by extraction from substances
of vegetable origin, or independently by means of chemical
synthesis, or by a combination of extraction and chemical
synthesis:
(1) opium, opiates, derivatives of opium and opiates,
including their isomers, esters, ethers, salts, and salts

SB3025 - 60 - LRB102 20970 SPS 29867 b
of isomers, esters, and ethers, whenever the existence of
such isomers, esters, ethers, and salts is possible within
the specific chemical designation; however the term
"narcotic drug" does not include the isoquinoline
alkaloids of opium;
(2) (blank);
(3) opium poppy and poppy straw;
(4) coca leaves, except coca leaves and extracts of
coca leaves from which substantially all of the cocaine
and ecgonine, and their isomers, derivatives and salts,
have been removed;
(5) cocaine, its salts, optical and geometric isomers,
and salts of isomers;
(6) ecgonine, its derivatives, their salts, isomers,
and salts of isomers;
(7) any compound, mixture, or preparation which
contains any quantity of any of the substances referred to
in subparagraphs (1) through (6).
(bb) "Nurse" means a registered nurse licensed under the
Nurse Practice Act.
(cc) (Blank).
(dd) "Opiate" means any substance having an addiction
forming or addiction sustaining liability similar to morphine
or being capable of conversion into a drug having addiction
forming or addiction sustaining liability.
(ee) "Opium poppy" means the plant of the species Papaver

SB3025 - 61 - LRB102 20970 SPS 29867 b
somniferum L., except its seeds.
(ee-5) "Oral dosage" means a tablet, capsule, elixir, or
solution or other liquid form of medication intended for
administration by mouth, but the term does not include a form
of medication intended for buccal, sublingual, or transmucosal
administration.
(ff) "Parole and Pardon Board" means the Parole and Pardon
Board of the State of Illinois or its successor agency.
(gg) "Person" means any individual, corporation,
mail-order pharmacy, government or governmental subdivision or
agency, business trust, estate, trust, partnership or
association, or any other entity.
(hh) "Pharmacist" means any person who holds a license or
certificate of registration as a registered pharmacist, a
local registered pharmacist or a registered assistant
pharmacist under the Pharmacy Practice Act.
(ii) "Pharmacy" means any store, ship or other place in
which pharmacy is authorized to be practiced under the
Pharmacy Practice Act.
(ii-5) "Pharmacy shopping" means the conduct prohibited
under subsection (b) of Section 314.5 of this Act.
(ii-10) "Physician" (except when the context otherwise
requires) means a person licensed to practice medicine in all
of its branches.
(jj) "Poppy straw" means all parts, except the seeds, of
the opium poppy, after mowing.

SB3025 - 62 - LRB102 20970 SPS 29867 b
(kk) "Practitioner" means a physician licensed to practice
medicine in all its branches, dentist, optometrist, podiatric
physician, naturopathic physician, veterinarian, scientific
investigator, pharmacist, physician assistant, advanced
practice registered nurse, licensed practical nurse,
registered nurse, emergency medical services personnel,
hospital, laboratory, or pharmacy, or other person licensed,
registered, or otherwise lawfully permitted by the United
States or this State to distribute, dispense, conduct research
with respect to, administer or use in teaching or chemical
analysis, a controlled substance in the course of professional
practice or research.
(ll) "Pre-printed prescription" means a written
prescription upon which the designated drug has been indicated
prior to the time of issuance; the term does not mean a written
prescription that is individually generated by machine or
computer in the prescriber's office.
(mm) "Prescriber" means a physician licensed to practice
medicine in all its branches, dentist, optometrist,
naturopathic physician, prescribing psychologist licensed
under Section 4.2 of the Clinical Psychologist Licensing Act
with prescriptive authority delegated under Section 4.3 of the
Clinical Psychologist Licensing Act, podiatric physician, or
veterinarian who issues a prescription, a physician assistant
who issues a prescription for a controlled substance in
accordance with Section 303.05, a written delegation, and a

SB3025 - 63 - LRB102 20970 SPS 29867 b
written collaborative agreement required under Section 7.5 of
the Physician Assistant Practice Act of 1987, an advanced
practice registered nurse with prescriptive authority
delegated under Section 65-40 of the Nurse Practice Act and in
accordance with Section 303.05, a written delegation, and a
written collaborative agreement under Section 65-35 of the
Nurse Practice Act, an advanced practice registered nurse
certified as a nurse practitioner, nurse midwife, or clinical
nurse specialist who has been granted authority to prescribe
by a hospital affiliate in accordance with Section 65-45 of
the Nurse Practice Act and in accordance with Section 303.05,
or an advanced practice registered nurse certified as a nurse
practitioner, nurse midwife, or clinical nurse specialist who
has full practice authority pursuant to Section 65-43 of the
Nurse Practice Act.
(nn) "Prescription" means a written, facsimile, or oral
order, or an electronic order that complies with applicable
federal requirements, of a physician licensed to practice
medicine in all its branches, dentist, podiatric physician,
naturopathic physician, or veterinarian for any controlled
substance, of an optometrist in accordance with Section 15.1
of the Illinois Optometric Practice Act of 1987, of a
prescribing psychologist licensed under Section 4.2 of the
Clinical Psychologist Licensing Act with prescriptive
authority delegated under Section 4.3 of the Clinical
Psychologist Licensing Act, of a physician assistant for a

SB3025 - 64 - LRB102 20970 SPS 29867 b
controlled substance in accordance with Section 303.05, a
written delegation, and a written collaborative agreement
required under Section 7.5 of the Physician Assistant Practice
Act of 1987, of an advanced practice registered nurse with
prescriptive authority delegated under Section 65-40 of the
Nurse Practice Act who issues a prescription for a controlled
substance in accordance with Section 303.05, a written
delegation, and a written collaborative agreement under
Section 65-35 of the Nurse Practice Act, of an advanced
practice registered nurse certified as a nurse practitioner,
nurse midwife, or clinical nurse specialist who has been
granted authority to prescribe by a hospital affiliate in
accordance with Section 65-45 of the Nurse Practice Act and in
accordance with Section 303.05 when required by law, or of an
advanced practice registered nurse certified as a nurse
practitioner, nurse midwife, or clinical nurse specialist who
has full practice authority pursuant to Section 65-43 of the
Nurse Practice Act.
(nn-5) "Prescription Information Library" (PIL) means an
electronic library that contains reported controlled substance
data.
(nn-10) "Prescription Monitoring Program" (PMP) means the
entity that collects, tracks, and stores reported data on
controlled substances and select drugs pursuant to Section
316.
(oo) "Production" or "produce" means manufacture,

SB3025 - 65 - LRB102 20970 SPS 29867 b
planting, cultivating, growing, or harvesting of a controlled
substance other than methamphetamine.
(pp) "Registrant" means every person who is required to
register under Section 302 of this Act.
(qq) "Registry number" means the number assigned to each
person authorized to handle controlled substances under the
laws of the United States and of this State.
(qq-5) "Secretary" means, as the context requires, either
the Secretary of the Department or the Secretary of the
Department of Financial and Professional Regulation, and the
Secretary's designated agents.
(rr) "State" includes the State of Illinois and any state,
district, commonwealth, territory, insular possession thereof,
and any area subject to the legal authority of the United
States of America.
(rr-5) "Stimulant" means any drug that (i) causes an
overall excitation of central nervous system functions, (ii)
causes impaired consciousness and awareness, and (iii) can be
habit-forming or lead to a substance abuse problem, including
but not limited to amphetamines and their analogs,
methylphenidate and its analogs, cocaine, and phencyclidine
and its analogs.
(rr-10) "Synthetic drug" includes, but is not limited to,
any synthetic cannabinoids or piperazines or any synthetic
cathinones as provided for in Schedule I.
(ss) "Ultimate user" means a person who lawfully possesses

SB3025 - 66 - LRB102 20970 SPS 29867 b
a controlled substance for his or her own use or for the use of
a member of his or her household or for administering to an
animal owned by him or her or by a member of his or her
household.
(Source: P.A. 100-280, eff. 1-1-18; 100-453, eff. 8-25-17;
100-513, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff.
8-14-18; 101-666, eff. 1-1-22.)
Section 995. No acceleration or delay. Where this Act
makes changes in a statute that is represented in this Act by
text that is not yet or no longer in effect (for example, a
Section represented by multiple versions), the use of that
text does not accelerate or delay the taking effect of (i) the
changes made by this Act or (ii) provisions derived from any
other Public Act.
Section 999. Effective date. This Act takes effect upon
becoming law.